- Home
- VRAX vs RDHL Comparison
VRAX vs RDHL Comparison
Compare VRAX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- RDHL
- Stock Information
- Founded
- VRAX 2013
- RDHL 2009
- Country
- VRAX United Kingdom
- RDHL Israel
- Employees
- VRAX N/A
- RDHL N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- RDHL Health Care
- Exchange
- VRAX Nasdaq
- RDHL Nasdaq
- Market Cap
- VRAX 7.3M
- RDHL 8.2M
- IPO Year
- VRAX 2022
- RDHL N/A
- Fundamental
- Price
- VRAX $1.63
- RDHL $5.58
- Analyst Decision
- VRAX
- RDHL
- Analyst Count
- VRAX 0
- RDHL 0
- Target Price
- VRAX N/A
- RDHL N/A
- AVG Volume (30 Days)
- VRAX 253.3K
- RDHL 10.4K
- Earning Date
- VRAX 02-05-2025
- RDHL 04-07-2025
- Dividend Yield
- VRAX N/A
- RDHL N/A
- EPS Growth
- VRAX N/A
- RDHL N/A
- EPS
- VRAX N/A
- RDHL N/A
- Revenue
- VRAX $84,872.00
- RDHL $3,707,000.00
- Revenue This Year
- VRAX $5,169.18
- RDHL $224.90
- Revenue Next Year
- VRAX $66.97
- RDHL $82.69
- P/E Ratio
- VRAX N/A
- RDHL N/A
- Revenue Growth
- VRAX 7.03
- RDHL N/A
- 52 Week Low
- VRAX $0.60
- RDHL $5.41
- 52 Week High
- VRAX $9.00
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- VRAX 38.98
- RDHL 35.64
- Support Level
- VRAX $1.58
- RDHL $5.50
- Resistance Level
- VRAX $2.29
- RDHL $6.26
- Average True Range (ATR)
- VRAX 0.22
- RDHL 0.32
- MACD
- VRAX -0.04
- RDHL -0.02
- Stochastic Oscillator
- VRAX 11.77
- RDHL 3.08
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.